Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Neurological disorders

- PMLiVE

Novo Nordisk’s Victoza shows Alzheimer’s benefits

UK scientists say the diabetes drug could reverse effects of dementia

- PMLiVE

Alzheimer’s disease pipeline takes multiple hits

Following a number of recent failures of clinical compounds, researchers are shifting the focus from late-stage disease to early-stage or prophylactic therapies

- PMLiVE

FDA fast-tracks Elan’s Alzheimer’s drug

Speeds up regulatory process for ELND005 for the treatment of neuropsychiatric symptoms

- PMLiVE

Merck maintains lead in BACE inhibitors for Alzheimer’s

Positive results in phase Ib study in patients with Alzheimer’s disease

- PMLiVE

Safety fears force Lilly to halt BACE inhibitor trial in Alzheimer’s

Patients experience abnormal liver functions in trial

- PMLiVE

Baxter’s Gammagard latest disappointment in Alzheimer’s

Fails to show improvement in cognitive and functional measures

- PMLiVE

Otsuka licenses Lundbeck’s Alzheimer’s drug in $825m deal

Lu AE58054 is in phase III development as add-on to donepezil

- PMLiVE

FDA explains draft Alzheimer’s guidance in NEJM editorial

Intends to relax requirements in patient function and cognition

- PMLiVE

FDA proffers guidance for new Alzheimer’s drugs

Encourages approach that tackles disease in its early stages

Canadian charity aims to tackle stigma of dementia

Alzheimer Society launches campaign during its Alzheimer’s Awareness Month

Daiichi Sankyo launches Alzheimer’s campaign

Disease awareness drive will include TV commercials, newspaper adverts and a website

EISAI

Eisai forms neurology partnership with UCL

Unique ‘therapeutic innovation group’ will research Alzheimer's, Parkinson's and other brain conditions

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links